Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
- PMID: 26973383
- PMCID: PMC4779910
- DOI: 10.3748/wjg.v22.i10.2869
Hepatogenous diabetes: Is it a neglected condition in chronic liver disease?
Abstract
Diabetes mellitus (DM) that occurs because of chronic liver disease (CLD) is known as hepatogenous diabetes (HD). Although the association of diabetes and liver cirrhosis was described forty years ago, it was scarcely studied for long time. Patients suffering from this condition have low frequency of risk factors of type 2 DM. Its incidence is higher in CLD of viral, alcoholic and cryptogenic etiology. Its pathophysiology relates to liver damage, pancreatic dysfunction, interactions between hepatitis C virus (HCV) and glucose metabolism mechanisms and genetic susceptibility. It associates with increased rate of liver complications and hepatocellular carcinoma, and decreased 5-year survival rate. It reduces sustained virological response in HCV infected patients. In spite of these evidences, the American Diabetes Association does not recognize HD. In addition, the impact of glucose control on clinical outcomes of patients has not been evaluated. Treatment of diabetes may be difficult due to liver insufficiency and hepatotoxicity of antidiabetic drugs. Notwithstanding, no therapeutic guidelines have been implemented up to date. In this editorial, authors discuss the reasons why they think that HD may be a neglected pathological condition and call attention to the necessity for more clinical research on different fields of this disease.
Keywords: Chronic liver disease; Diabetes mellitus; Hepatitis C virus; Hepatogenous diabetes; Outcomes; Therapy.
Similar articles
-
Hepatogenous diabetes. Current views of an ancient problem.Ann Hepatol. 2009 Jan-Mar;8(1):13-20. Ann Hepatol. 2009. PMID: 19221528 Review.
-
Severity of liver disease predicts the development of glucose abnormalities in patients with chronic hepatitis B or C following achievement of sustained virological response to antiviral therapy.J Med Virol. 2009 Apr;81(4):610-8. doi: 10.1002/jmv.21396. J Med Virol. 2009. PMID: 19235842
-
Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.Am J Gastroenterol. 2008 Oct;103(10):2481-7. doi: 10.1111/j.1572-0241.2008.02002.x. Epub 2008 Aug 8. Am J Gastroenterol. 2008. PMID: 18702647 Clinical Trial.
-
Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?Liver Int. 2017 Jul;37(7):950-962. doi: 10.1111/liv.13337. Epub 2016 Dec 31. Liver Int. 2017. PMID: 27943508 Review.
-
Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.World J Gastroenterol. 2015 Dec 14;21(46):12989-95. doi: 10.3748/wjg.v21.i46.12989. World J Gastroenterol. 2015. PMID: 26675364 Free PMC article. Review.
Cited by
-
Hepatogenous Diabetes - A Report from Central India.J Clin Exp Hepatol. 2022 Mar-Apr;12(2):312-318. doi: 10.1016/j.jceh.2021.08.018. Epub 2021 Aug 25. J Clin Exp Hepatol. 2022. PMID: 35535090 Free PMC article.
-
Clinical implications of diabetes in chronic liver disease: Diagnosis, outcomes and management, current and future perspectives.World J Gastroenterol. 2022 Feb 28;28(8):775-793. doi: 10.3748/wjg.v28.i8.775. World J Gastroenterol. 2022. PMID: 35317103 Free PMC article. Review.
-
A Different Perspective for Management of Diabetes Mellitus: Controlling Viral Liver Diseases.J Diabetes Res. 2017;2017:5625371. doi: 10.1155/2017/5625371. Epub 2017 Mar 2. J Diabetes Res. 2017. PMID: 28352640 Free PMC article. Review.
-
[Hepatogenic diabetes: three cases report and literature review].Probl Endokrinol (Mosk). 2025 May 20;71(2):66-74. doi: 10.14341/probl13443. Probl Endokrinol (Mosk). 2025. PMID: 40411331 Free PMC article. Review. Russian.
-
Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus.J Diabetes Res. 2021 Nov 11;2021:7692447. doi: 10.1155/2021/7692447. eCollection 2021. J Diabetes Res. 2021. PMID: 34805412 Free PMC article. Review.
References
-
- García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, Reyes-Cabello E, González-González JA, Muñoz-Espinosa LE, Vázquez-Elizondo G, Villarreal-Pérez JZ, Maldonado-Garza HJ. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Ann Hepatol. 2012;11:240–248. - PubMed
-
- Grancini V, Trombetta M, Lunati ME, Zimbalatti D, Boselli ML, Gatti S, Donato MF, Resi V, D’Ambrosio R, Aghemo A, et al. Contribution of β-cell dysfunction and insulin resistance to cirrhosis-associated diabetes: Role of severity of liver disease. J Hepatol. 2015;63:1484–1490. - PubMed
-
- García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ. Current Concepts in Diabetes Mellitus and Chronic Liver Disease: Clinical Outcomes, Hepatitis C Virus Association, and Therapy. Dig Dis Sci. 2016;61:371–380. - PubMed
-
- Conn HO, Schreiber W, Elkington SG, Johnson TR. Cirrhosis and diabetes. I. Increased incidence of diabetes in patients with Laennec’s cirrhosis. Am J Dig Dis. 1969;14:837–852. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous